-
Price Momentum
FRNM is trading near the bottom of its 52-week range and below its 200-day simple moving average.
-
Price change
The price of FRNM shares has decreased $0.29 since the market last closed. This is a 2.77% drop.
-
Closed at $10.18.
The stock has since risen $0.12 in after-hours trading.
Key terms
About FRNM
Freenome, Inc. operates as an early detection company, which engages in the development of blood-based screening tests to detect cancer. Its proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. The company was founded by Riley Ennis in 2014 and is headquartered in Brisbane, CA.
-
Market cap: $1.09B
A market capitalization between $300 million and $2 billion places FRNM in the small capitalization category.
Key terms
Smart score
Latest FRNM news
FRNM Financials
-
FRNM total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight.
-
Net income: $837.47K (1Y), -$114.94K (Q2)
Net Income decreased 56.16% since last year and decreased 122.12% since last quarter.
-
Earnings per share: $0.08 (1Y), -$0.01 (Q2)
EPS decreased 56.14% since last year and decreased 136.17% since last quarter.
Key terms
FRNM Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
FRNM Competitors
-
How competitors are chosen
FRNM's competitors are included in the Health Technology sector and Medical Specialties group
-
Market cap: $1.09B
A market capitalization between $300 million and $2 billion places FRNM in the small capitalization category.
